⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,121.95
−0.09%
Brent
$109.08
−0.12%
BTC
$82,970.30
+1.38%
ETH
$2,455.06
+2.07%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
165,151.64
−0.49%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,121.95
−0.09%
Brent
$109.08
−0.12%
BTC
$82,970.30
+1.38%
ETH
$2,455.06
+2.07%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› IRON
D
Disc Medicine Inc
NAS:IRON
Healthcare
CBOEFTSE:MRUT
NASDAQ:NBI
$79.48
+0.70%
At close
At close · Wed 21 Oct · ≈
AED 291.89
· Market cap
$3.05B
· Next earnings
Thu 5 Nov
· Extended
$79.00
−0.60%
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Disc Medicine Inc · News · TradingHolo
IRON news
Headlines tagged to this company
RE
Disc Medicine Announces Proposed $350 Million Public Offering Of Common Stock And Pre-Funded Warrants
Reuters · 25 h ago
SE
Disc Medicine launches $350M public offering of common stock and pre-funded warrants
Seeking Alpha · 27 h ago
GL
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire · 27 h ago
DO
Disc Medicine Price Target Raised to $120.00/Share From $100.00 by BMO Capital
Dow Jones Newswires · 29 h ago
DO
Under the Radar: Disc Shares Jump as Pill for Sunlight Disorder Succeeds in Study — WSJ
Dow Jones Newswires · 31 h ago
RE
Disc Medicine's late-stage win clears path for approval of sun-allergy pill
Reuters · 31 h ago
DO
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes — Barrons.com
Dow Jones Newswires · 31 h ago
DO
Disc Medicine Shares Gain on Positive Trial Results for Erythropoietic Protoporphyria Treatment
Dow Jones Newswires · 32 h ago
DO
Disc Medicine Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones Newswires · 32 h ago
TR
Cantor Fitzgerald maintains Overweight rating on Disc Medicine, $170 price target
TradingView · 32 h ago
RE
Disc Medicine's rare disease drug succeeds in late-stage trial
Reuters · 35 h ago
RE
Disc Medicine Announces Success On All Primary And Secondary Endpoints In The Pivotal Phase 3 Apollo Trial Of Bitopertin In Adults And Adolescents With Erythropoietic Protoporphyria (Epp)
Reuters · 35 h ago
SE
Disc Medicine posts late-stage trial win for lead asset developed with Roche
Seeking Alpha · 35 h ago
TR
Disc Medicine: Phase 3 APOLLO shows significant PPIX reduction, +12.2 hrs pain-free light time
TradingView · 2 d ago
GL
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
GlobeNewswire · 2 d ago
SE
Disc Medicine rallies 32% as investors await bitopertin trial results
Seeking Alpha · 2 d ago
GL
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
GlobeNewswire · 2 d ago
BE
Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones
benzinga · 40 d ago
GL
Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting
globenewswire · 41 d ago
GL
Disc Medicine to Participate in Upcoming Investor Conferences
globenewswire · 48 d ago
More news →